文献速递垂体与肾上腺疾病性腺与生殖内分泌

男性大泌乳素瘤在卡麦角林治疗泌乳素正常后持续性低促性腺激素性性腺功能减退的预测因素

Predictors of Chronic LH-Testosterone Axis Suppression in Male Macroprolactinomas With Normoprolactinemia on Cabergoline.
PubMed 文献 · J Clin Endocrinol Metab · 2020-01-01

该回顾性研究纳入30例基线有低促性腺激素性性腺功能减退(HH)且经卡麦角林单药治疗达泌乳素正常的男性大泌乳素瘤患者,中位随访3年,仅8例(26.7%)恢复性腺功能。基线泌乳素和最大肿瘤直径较低者更易恢复性腺功能;基线最大肿瘤直径≤3.2 cm和血清泌乳素≤2098 ng/mL可预测HH逆转。

要点

  • 卡麦角林治疗后仅26.7%男性大泌乳素瘤患者恢复LH-睾酮轴功能。
  • 基线肿瘤越大、泌乳素越高,持续性HH风险越高。
  • 肿瘤直径≤3.2 cm和泌乳素≤2098 ng/mL提示HH可能逆转。

核心结论

  • 男性大泌乳素瘤患者经卡麦角林单药治疗达泌乳素正常后,26.7%恢复LH-睾酮轴功能。
  • 基线肿瘤较大和血清泌乳素较高预测持续性HH。
  • 数据支持持续性HH源于下丘脑-垂体-性腺轴慢性功能改变而非促性腺激素细胞损伤。

研究设计与样本

  • 回顾性研究,采用前瞻性横断面评估,在三级医疗中心进行。
  • 纳入30例基线有HH且经卡麦角林单药治疗达泌乳素正常的男性大泌乳素瘤患者,年龄38.3±10.1岁,基线肿瘤大小4.08±1.48 cm,泌乳素中位数2871 ng/mL(四分位距1665-8425 ng/mL),中位随访3年。

主要发现

  • 30例中8例在中位随访3年后达到性腺功能正常。
  • 持续性HH患者LH-睾酮轴受抑制,但其他前叶垂体激素轴包括FSH-抑制素B未受累。
  • 达到性腺功能正常者基线泌乳素较低(1674 vs 4120 ng/mL;P = .008),最大肿瘤直径较小(2.55±0.36 vs 4.64±1.32 cm;P = .003)。

关键数值与推荐

  • 基线最大肿瘤直径≤3.2 cm预测HH逆转的敏感性75%、特异性63.6%。
  • 血清泌乳素≤2098 ng/mL预测HH逆转的敏感性87.5%、特异性77.3%。

临床怎么用

  • 对男性大泌乳素瘤伴HH患者,卡麦角林治疗达泌乳素正常后应评估性腺功能恢复情况。
  • 基线肿瘤直径和泌乳素水平可用于预测持续性HH风险,辅助临床决策。

局限性

  • 样本量较小(30例)。
  • 回顾性设计。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Data are limited regarding prevalence, predictors, and mechanisms of persistent hypogonadotropic hypogonadism (HH) in males with a macroprolactinoma who achieve normoprolactinemia on dopamine-agonist therapy. None of the previous studies provide cutoffs to predict the achievement of eugonadism. OBJECTIVE: The objective of this work is to evaluate the prevalence of persistent HH and its determinants in men with a macroprolactinoma who achieve normoprolactinemia on cabergoline monotherapy. DESIGN AND SETTING: This retrospective study with prospective cross-sectional evaluation took place at a tertiary health care center. PATIENTS: Study participants included men with a macroprolactinoma and baseline HH who achieved normoprolactinemia on cabergoline monotherapy. MAIN OUTCOME MEASURES: Outcome measures of this study included the prevalence of persistent HH and its predictors. RESULTS: Thirty participants (age, 38.3 ± 10.1 years) with baseline tumor size of 4.08 ± 1.48 cm and median (interquartile range) prolactin of 2871 ng/mL (range, 1665-8425 ng/mL) were included. Eight of 30 participants achieved eugonadism after a median follow-up of 3 years. Patients with persistent HH had suppression of the luteinizing hormone (LH)-testosterone axis with sparing of other anterior pituitary hormonal axes, including follicle-stimulating hormone-inhibin B. Baseline prolactin (1674 vs 4120 ng/mL; P = .008) and maximal tumor diameter (2.55 ± 0.36 vs 4.64 ± 1.32 cm; P = .003) were lower in patients who achieved eugonadism. Baseline maximal tumor diameter less than or equal to 3.2 cm (sensitivity: 75%, specificity: 63.6%) and serum prolactin less than or equal to 2098 ng/mL (sensitivity: 87.5%, specificity: 77.3%) best predicted reversal of HH. CONCLUSION: Recovery of the LH-testosterone axis occurred in 26.7% of men with a macroprolactinoma who achieved normoprolactinemia on cabergoline monotherapy. Higher baseline tumor size and serum prolactin predict persistent HH. Our data favor chronic functional modification of the hypothalamic-pituitary-gonadal axis over gonadotroph damage as the cause of persistent HH.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Sehemby M, Lila AR, Sarathi V, et al. Predictors of Chronic LH-Testosterone Axis Suppression in Male Macroprolactinomas With Normoprolactinemia on Cabergoline. J Clin Endocrinol Metab. 2020. PMID: 32942295. doi:10.1210/clinem/dgaa650

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。